Literature DB >> 18191832

Morphine sex-dependently induced place conditioning in adult Wistar rats.

Manizheh Karami1, Mohammad Reza Zarrindast.   

Abstract

The present study was conducted to investigate the potential sex-differences in morphine-induced conditioned place preference. A 3-day unbiased conditioning procedure was used to establish conditioned place preference in adult male and female Wistar rats (weighing 200-250 g). The effect of morphine on locomotor activity of subjects was also studied. Naloxone (0.5-2 mg/kg, i.p.), a selective antagonist of mu-opioid receptor or sulpiride (0.5-2 mg/kg, s.c.), a selective antagonist of dopamine D(2) receptor was administered, during conditioning, to indicate the receptor-mediated mechanisms governing upon possible sex-differences to the opioid response. Results show that morphine (0.5-10 mg/kg, s.c.) differently produced a significant place preference in female and male Wistar rats. Although, the opioid maximum response in both sexes was observed at 7.5 mg/kg, but, it was found that female rats acquired conditioned place preference at a lower dose (0.5 mg/kg, s.c.) of morphine compared to male rats. Moreover, the increase in morphine-induced response at higher doses (5-10 mg/kg, s.c.) was more pronounced in females than the males, indicating that female Wistar rats are more sensitive to the place conditioning induced by morphine. Also, the females were more sensitive to locomotor activation induced by morphine at least at one dose (7.5 mg/kg). Animals' body-weight at 10 mg/kg of opioid was increased, the effect that was not dependent to sex. The results also demonstrate that naloxone (1 and 2 mg/kg, i.p.) induced a significant place preference in two sexes with no significant effect on animals' locomotor activity. The antagonist in males but not in females showed a significant effect on animals' body-weight. Naloxone (0.5-2 mg/kg, i.p.) prior-administration to morphine, during conditioning, attenuated the opioid response in two sexes. The attenuation of the morphine response was more pronounced in males than the other sex at the higher dose (2 mg/kg) of the antagonist. In addition, the preadministration of naloxone, during morphine conditioning, both attenuated the drug-induced hyperactivity in females and decreased the animals' body-weight, albeit more effectively in females than the males. Sulpiride injections (1 and 2 mg/kg s.c.), during the conditioning period, induced a significant aversion in males but not in females with no significant effect either on locomotor activity or body-weight in both sexes. When sulpiride (0.5-2 mg/kg, s.c.), during conditioning, was morphine pre-injected, the antagonist at higher doses significantly attenuated the opioid response in males, reflecting the involvement of dopamine D(2) receptor in sex-dependent morphine-conditioned place preference. Prior-injections of sulpiride to morphine produced a significant effect on locomotor activity of females. The effect of the antagonist preinjections on body-weight was also observed in males. Present results indicate sex-differences both in reinforcing and locomotor activity effects of morphine in Wistar rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18191832     DOI: 10.1016/j.ejphar.2007.12.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

Review 1.  Sex Differences in Animal Models: Focus on Addiction.

Authors:  Jill B Becker; George F Koob
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

Review 2.  Aberrant learning and memory in addiction.

Authors:  Mary M Torregrossa; Philip R Corlett; Jane R Taylor
Journal:  Neurobiol Learn Mem       Date:  2011-03-03       Impact factor: 2.877

Review 3.  CRF modulation of central monoaminergic function: Implications for sex differences in alcohol drinking and anxiety.

Authors:  Kristen E Pleil; Mary Jane Skelly
Journal:  Alcohol       Date:  2018-02-02       Impact factor: 2.405

Review 4.  Sex-dependent mental illnesses and mitochondria.

Authors:  Akiko Shimamoto; Virginie Rappeneau
Journal:  Schizophr Res       Date:  2017-03-06       Impact factor: 4.939

5.  Abuse Liability, Anti-Nociceptive, and Discriminative Stimulus Properties of IBNtxA.

Authors:  Ariful Islam; Mohammad Atiqur Rahman; Megan B Brenner; Allamar Moore; Alyssa Kellmyer; Harley M Buechler; Frank DiGiorgio; Vincent R Verchio; Laura McCracken; Mousumi Sumi; Robert Hartley; Joseph R Lizza; Gustavo Moura-Letts; Bradford D Fischer; Thomas M Keck
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-27

6.  Sex Differences in the Rat Hippocampal Opioid System After Oxycodone Conditioned Place Preference.

Authors:  James D Ryan; Yan Zhou; Natalina H Contoreggi; Farah K Bshesh; Jason D Gray; Joshua F Kogan; Konrad T Ben; Bruce S McEwen; Mary Jeanne Kreek; Teresa A Milner
Journal:  Neuroscience       Date:  2018-10-11       Impact factor: 3.590

Review 7.  Brain-derived neurotrophic factor-estrogen interactions in the hippocampal mossy fiber pathway: implications for normal brain function and disease.

Authors:  L C Harte-Hargrove; N J Maclusky; H E Scharfman
Journal:  Neuroscience       Date:  2012-12-29       Impact factor: 3.590

Review 8.  Sex differences in opioid receptor mediated effects: Role of androgens.

Authors:  Jessica L Sharp; Tallia Pearson; Mark A Smith
Journal:  Neurosci Biobehav Rev       Date:  2022-01-04       Impact factor: 8.989

9.  Compensatory Role of Insulin in the Extinction but Not Reinstatement of Morphine-Induced Conditioned Place Preference in the Streptozotocin-Induced Diabetic Rats.

Authors:  Atieh Chizari; Rezvan Hassanpour; Saeideh Karimi-Haghighi; Ronak Azizbeigi; Somaye Mesgar; Zahra Mousavi; Abbas Haghparast
Journal:  Neurochem Res       Date:  2022-02-21       Impact factor: 3.996

10.  Effects of sex and remifentanil dose on rats' acquisition of responding for a remifentanil-conditioned reinforcer.

Authors:  Jeremiah W Bertz; Emily L Jackson; Davina R Barron; James H Woods
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.